NASDAQ:NTLA Intellia Therapeutics (NTLA) Stock Price, News & Analysis $19.72 -1.21 (-5.78%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$19.51▼$21.3350-Day Range$19.72▼$27.3652-Week Range$19.37▼$38.71Volume1.42 million shsAverage Volume1.51 million shsMarket Capitalization$1.90 billionP/E RatioN/ADividend YieldN/APrice Target$61.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Intellia Therapeutics alerts: Email Address Intellia Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.79 Rating ScoreUpside/Downside212.3% Upside$61.58 Price TargetShort InterestBearish14.32% of Shares Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment-0.10Based on 6 Articles This WeekInsider TradingSelling Shares$9,287 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($5.19) to ($5.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.95 out of 5 starsMedical Sector162nd out of 910 stocksDiagnostic Substances Industry4th out of 14 stocks 4.4 Analyst's Opinion Consensus RatingIntellia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIntellia Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Intellia Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.32% of the outstanding shares of Intellia Therapeutics have been sold short.Short Interest Ratio / Days to CoverIntellia Therapeutics has a short interest ratio ("days to cover") of 8.4.Change versus previous monthShort interest in Intellia Therapeutics has recently increased by 3.37%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIntellia Therapeutics does not currently pay a dividend.Dividend GrowthIntellia Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIntellia Therapeutics has received a 74.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for genetic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Intellia Therapeutics is -0.67. Previous Next 1.1 News and Social Media Coverage News SentimentIntellia Therapeutics has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Intellia Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for NTLA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Intellia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Intellia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,287.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Intellia Therapeutics is held by insiders.Percentage Held by Institutions88.77% of the stock of Intellia Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intellia Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Intellia Therapeutics are expected to decrease in the coming year, from ($5.19) to ($5.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intellia Therapeutics is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intellia Therapeutics is -3.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntellia Therapeutics has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Intellia Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Intellia Therapeutics Stock (NASDAQ:NTLA)Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Read More NTLA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTLA Stock News HeadlinesSeptember 6 at 4:07 PM | finance.yahoo.comIntellia Therapeutics, Inc.'s (NASDAQ:NTLA) latest 6.7% decline adds to one-year losses, institutional investors may consider drastic measuresSeptember 5 at 1:01 AM | americanbankingnews.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $61.58 Consensus Price Target from BrokeragesSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 3, 2024 | markets.businessinsider.comIntellia Therapeutics (NTLA) Receives a Buy from Truist FinancialSeptember 3, 2024 | globenewswire.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 1, 2024 | americanbankingnews.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Down 3.6%August 27, 2024 | money.usnews.comIntellia Therapeutics IncAugust 20, 2024 | uk.finance.yahoo.comNTLA Sep 2024 22.500 callSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 18, 2024 | nasdaq.comInteresting NTLA Put And Call Options For April 2025August 14, 2024 | msn.comIntellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health AdvancementsAugust 13, 2024 | markets.businessinsider.comMaintaining Hold on Intellia Therapeutics Amid Financial Stability and Competitive PressuresAugust 13, 2024 | msn.com3 High-Risk Undervalued Stocks for Aggressive Investors Targeting 35%+ UpsideAugust 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash ReservesAugust 12, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)August 10, 2024 | finance.yahoo.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportAugust 9, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)August 9, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Intellia Therapeutics (NTLA)See More Headlines Receive NTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NTLA CUSIPN/A CIK1652130 Webwww.intelliatx.com Phone(857) 285-6200FaxN/AEmployees600Year FoundedN/APrice Target and Rating Average Stock Price Target$61.58 High Stock Price Target$120.00 Low Stock Price Target$29.00 Potential Upside/Downside+212.3%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($5.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-481,190,000.00 Net MarginsN/A Pretax Margin-1,106.87% Return on Equity-47.12% Return on Assets-38.62% Debt Debt-to-Equity RatioN/A Current Ratio7.21 Quick Ratio7.21 Sales & Book Value Annual Sales$45.97 million Price / Sales41.39 Cash FlowN/A Price / Cash FlowN/A Book Value$9.56 per share Price / Book2.06Miscellaneous Outstanding Shares96,475,000Free Float93,581,000Market Cap$1.90 billion OptionableOptionable Beta1.81 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. John M. Leonard M.D. (Age 67)President, CEO & Director Comp: $1.06MMr. Glenn G. Goddard CPA (Age 53)Executive VP, CFO & Treasurer Comp: $630.91kDr. Laura Sepp-Lorenzino Ph.D. (Age 63)Executive VP & Chief Scientific Officer Comp: $670.58kMr. James E. Basta Esq. (Age 58)J.D., Executive VP, General Counsel & Corporate Secretary Comp: $616.15kDr. David Lebwohl M.D. (Age 69)Executive VP & Chief Medical Officer Comp: $671.42kMr. Derek Hicks (Age 50)Executive VP & Chief Business Officer Comp: $823.42kMr. Nessan Bermingham Ph.D. (Age 51)Founder & Member of Scientific Advisor Board Comp: $1.38MDr. Rachel E. Haurwitz Ph.D. (Age 38)Co-Founder Dr. Andrew May Ph.D.Founder and Member of Scientific Advisor BoardDr. Jennifer A. Doudna Ph.D. (Age 60)Founder & Member of Scientific Advisor Board More ExecutivesKey CompetitorsMeridian BioscienceNASDAQ:VIVOCelldex TherapeuticsNASDAQ:CLDXCRISPR TherapeuticsNASDAQ:CRSPEditas MedicineNASDAQ:EDITSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 21,614 shares on 9/5/2024Ownership: 0.022%Algert Global LLCBought 51,572 shares on 8/16/2024Ownership: 0.071%Capital Impact Advisors LLCSold 5,439 shares on 8/16/2024Ownership: 0.028%Creative PlanningSold 5,094 shares on 8/16/2024Ownership: 0.013%The Manufacturers Life Insurance Company Sold 11,974 shares on 8/15/2024Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions NTLA Stock Analysis - Frequently Asked Questions How have NTLA shares performed this year? Intellia Therapeutics' stock was trading at $30.49 at the start of the year. Since then, NTLA shares have decreased by 35.3% and is now trading at $19.72. View the best growth stocks for 2024 here. How were Intellia Therapeutics' earnings last quarter? Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.29. The firm's revenue was down 48.5% compared to the same quarter last year. What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO? 12 employees have rated Intellia Therapeutics Chief Executive Officer John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among the company's employees. When did Intellia Therapeutics IPO? Intellia Therapeutics (NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are Intellia Therapeutics' major shareholders? Intellia Therapeutics' top institutional shareholders include ARK Investment Management LLC (12.02%), Sumitomo Mitsui Trust Holdings Inc. (3.38%), Federated Hermes Inc. (2.38%) and Dimensional Fund Advisors LP (1.37%). Insiders that own company stock include John M Leonard, James Basta, Eliana Clark, David Lebwohl, Laura Sepp-Lorenzino, Glenn Goddard and John F Crowley. View institutional ownership trends. How do I buy shares of Intellia Therapeutics? Shares of NTLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Intellia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Micron Technology (MU) and Advanced Micro Devices (AMD). This page (NASDAQ:NTLA) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
